APA

Cheng A., Thongprasert S., Lim H. Y., Sukeepaisarnjaroen W., Yang T., Wu C., Chao Y., Chan S. L., Kudo M., Ikeda M., Kang Y., Pan H., Numata K., Han G., Balsara B., Zhang Y., Rodriguez A., Zhang Y., Wang Y. & Poon R. T. P. (20170802). Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. : Hepatology (Baltimore, Md.).

Chicago

Cheng Ann-Lii, Thongprasert Sumitra, Lim Ho Yeong, Sukeepaisarnjaroen Wattana, Yang Tsai-Shen, Wu Cheng-Chung, Chao Yee, Chan Stephen L, Kudo Masatoshi, Ikeda Masafumi, Kang Yoon-Koo, Pan Hongming, Numata Kazushi, Han Guohong, Balsara Binaifer, Zhang Yong, Rodriguez Ana-Marie, Zhang Yi, Wang Yongyu and Poon Ronnie T P. 20170802. Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. : Hepatology (Baltimore, Md.).

Harvard

Cheng A., Thongprasert S., Lim H. Y., Sukeepaisarnjaroen W., Yang T., Wu C., Chao Y., Chan S. L., Kudo M., Ikeda M., Kang Y., Pan H., Numata K., Han G., Balsara B., Zhang Y., Rodriguez A., Zhang Y., Wang Y. and Poon R. T. P. (20170802). Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. : Hepatology (Baltimore, Md.).

MLA

Cheng Ann-Lii, Thongprasert Sumitra, Lim Ho Yeong, Sukeepaisarnjaroen Wattana, Yang Tsai-Shen, Wu Cheng-Chung, Chao Yee, Chan Stephen L, Kudo Masatoshi, Ikeda Masafumi, Kang Yoon-Koo, Pan Hongming, Numata Kazushi, Han Guohong, Balsara Binaifer, Zhang Yong, Rodriguez Ana-Marie, Zhang Yi, Wang Yongyu and Poon Ronnie T P. Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. : Hepatology (Baltimore, Md.). 20170802.